Amgen Inc.

AMGN

Healthcare Drug Manufacturers General

Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024.

Revenue
+8.45%
EPS
+19.4%
Free cash flow
−0.16%
Total debt
−1.06%

Quarter to September 2026, against a year earlier

460.42 0.14 +0.03%
Market cap
$248.8B
P/E
26.5×
Fwd P/E
23.7×
Dividend yield
2.16%
F-score
7/9
ROIC
14.3%
Net debt / EBITDA
2.9×
Dividend safety
56/100

Amgen Inc. (AMGN) P/E ratio

Alert me on P/E ratio

As of 6 November 2026, Amgen Inc. (AMGN) trades at a P/E ratio of 26.5×. Over the past ten years it has ranged from 13.2× (May 2019) to 75.3× (January 2018); the current reading is higher than 82% of that period. That is in line with the Drug Manufacturers General industry median of 26.5× and above the Healthcare sector median of 24.5×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 22.8× (33.22%)
FY2024 34.2× 44.46%
FY2023 23.7× 10.22%
FY2022 21.5× (1.07%)
FY2021 21.7× 17.02%
FY2020 18.6× (0.31%)
FY2019 18.6× 21.35%
FY2018 15.3× (77.21%)
FY2017 67.3× 360.78%
FY2016 14.6× (17.58%)

Quarterly newest first

Period P/E ratio Change
Sep 2026 24.2× 8.62%
Jun 2026 22.3× (8.12%)
Mar 2026 24.3× 6.38%
Dec 2025 22.8× 5.46%
43 more quarters

Against its own ten years

Low 13.2× High 75.3×
Ten-year median 20.7×
Current reading's percentile 80

P/E ratio against peers

Company P/E ratio
GILD Gilead Sciences, Inc. compare n/m
NVO Novo Nordisk A/S compare 10.1×
BMY Bristol Myers Squibb Company compare 13.7×
AZN AstraZeneca PLC compare 26.2×
AMGN Amgen Inc. 26.5×
NVS Novartis AG compare 30.9×
PFE Pfizer Inc. compare 41.3×
ABBV AbbVie Inc. compare 50.1×
MRK Merck & Co., Inc. compare 151×
Drug Manufacturers General industry median 26.5×
Healthcare sector median 24.5×
Market median 17.8×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on AMGN